Summary of Key Points
The National Medical Products Administration (NMPA) has recently launched the "Pioneer Plan" to solicit feedback, proposing the use of new methods such as organoids and AI models (NAMs) to reduce or replace animal trials in the development of innovative drugs, particularly the costly monkey trials. This is a global trend, and China is among the leading countries in related technologies. However, there are differing views within the industry regarding the adoption of these alternatives: some see it as a turning point, while others emphasize the need to verify the efficacy and safety of these methods. Currently, new methods can only be used for early screening and cannot completely replace animal trials. In the short term, pharmaceutical companies may face increased costs due to the parallel use of both old and new approaches. However, in the long run, it is essential to establish a regulatory-approved validation system to break the cycle of "which came first—the chicken or the egg?"
Detailed Explanation
1. Why Say Goodbye to Monkeys? Three Major Challenges with Traditional Trials
Traditional animal trials, especially those using monkeys, are increasingly unable to keep up with the pace of innovative drug development:
- Inaccurate Results: The physical structures and metabolic processes of monkeys differ from those of humans, which can lead to misleading trial outcomes when applied to humans (for example, a drug that is safe in monkeys may be problematic in humans).
- Exorbitant Costs: A complete preclinical trial requires 58 monkeys, with the cost of the monkeys alone accounting for half of the total expense, which can exceed 20 million yuan—more expensive than even Phase I human trials. Moreover, monkey prices are rising.
- International Pressure: Countries in Europe and America have already begun to promote alternatives to animal trials. Chinese pharmaceutical companies that want to market their drugs globally must align with regulatory bodies like the FDA; otherwise, they will not be able to apply for approval.
Increasing awareness of animal welfare has made "replacing monkeys" a common goal for both the industry and regulators.
2. Can New Methods Immediately Replace Monkeys? Despite Their Strengths, They Are Not Yet Fully Capable
New tools such as organoids (miniature organs created from human cells) and AI models represent cutting-edge technologies, but they still have significant limitations:
- AI Models: While they can design drug molecules, they cannot fully simulate the human body and cannot address cross-species uncertainties.
- Organoids: They lack blood vessels and cannot grow to a sufficient size to accurately mimic multi-organ interactions (e.g., the distribution and metabolism of drugs within the body).
Therefore, new methods are currently only useful for early screening—helping to identify candidates that are unlikely to be successful before investing heavily in animal trials. To completely replace key trial phases, we may need to wait several years or even a decade for further validation.
3. Will Pharmaceutical Companies Be Willing to Pay the Extra Cost? Most Are Hesitant, but Some Have a Critical Need
In the short term, companies will likely face additional costs due to the need to use both old and new methods (as regulatory approval has not yet been fully established). For example, the cost of developing small molecule drugs could increase by 2-5 million yuan, while large molecule drugs might see an increase of over 5 million yuan.
Most pharmaceutical companies are cautious, as most innovative drugs in China follow established targets validated abroad and prefer not to take risks with unproven new methods. However, there are specific areas (such as those involving the blood-brain barrier) where new methods are essential due to the lack of suitable animal models.
4. How Can New Methods Be Officially Recognized? A Reliable Validation System Is Needed
For new methods to be accepted by regulators, it is crucial to demonstrate their reliability:
- Unified Standards: All parties should use the same procedures (SOPs) and conduct blinded comparisons to verify whether the results predicted by the new methods match those of human clinical trials.
- Breaking the "Chicken or Egg" Dilemma: Pharmaceutical companies are reluctant to use unapproved methods, but regulatory approval requires extensive data, which in turn depends on these methods being used. China's CDE (Center for Drug Evaluation) and CNIA (China National Institute for Food and Drug Control) have already initiated multi-center validation efforts, modeled after the FDA’s ISTAND project, to address this issue.
Only by establishing a system that both buyers and regulators trust can new methods truly replace animal trials.
In Conclusion
Replacing animal trials is an inevitable trend, but there is still a long way to go. Currently, new methods serve as supplementary tools; they will only become the primary approach in the future. The key is to develop robust validation technologies and regulatory frameworks first.